Your browser doesn't support javascript.
loading
CFTR variant testing: a technical standard of the American College of Medical Genetics and Genomics (ACMG).
Deignan, Joshua L; Astbury, Caroline; Cutting, Garry R; Del Gaudio, Daniela; Gregg, Anthony R; Grody, Wayne W; Monaghan, Kristin G; Richards, Sue.
Afiliación
  • Deignan JL; Department of Pathology and Laboratory Medicine, University of California, Los Angeles, Los Angeles, CA, USA.
  • Astbury C; Department of Pathology and Laboratory Medicine, Cleveland Clinic, Cleveland, OH, USA.
  • Cutting GR; McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Del Gaudio D; Department of Human Genetics, The University of Chicago, Chicago, IL, USA.
  • Gregg AR; Department of Obstetrics and Gynecology, Baylor University Medical Center, Dallas, TX, USA.
  • Grody WW; Departments of Pathology and Laboratory Medicine, Pediatrics, and Human Genetics, University of California, Los Angeles, Los Angeles, CA, USA.
  • Monaghan KG; GeneDx, Gaithersburg, MD, USA.
  • Richards S; Department of Molecular and Medical Genetics, Knight Diagnostic Laboratories, Oregon Health & Science University, Portland, OR, USA.
Genet Med ; 22(8): 1288-1295, 2020 08.
Article en En | MEDLINE | ID: mdl-32404922
ABSTRACT
Pathogenic variants in the CFTR gene are causative of classic cystic fibrosis (CF) as well as some nonclassic CF phenotypes. In 2001, CF became the first target of pan-ethnic universal carrier screening by molecular methods. The American College of Medical Genetics and Genomics (ACMG) recommended a core panel of 23 disease-causing variants as the minimal set to be included in pan-ethnic carrier screening of individuals with no family history of the disease, and these variants were usually assessed using targeted methods. The original recommendation also left open the option for laboratories to offer expanded CFTR variant panels; however, at the time, expanded CFTR variant panels were met with some controversy on the basis of the available technologies and the limited phenotypic knowledge of rare variants. Both of those aspects have now evolved, prompting this update of the ACMG technical standards for CFTR variant testing.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Pruebas Genéticas / Regulador de Conductancia de Transmembrana de Fibrosis Quística / Genética Médica Tipo de estudio: Prognostic_studies Límite: Humans País/Región como asunto: America do norte Idioma: En Revista: Genet Med Asunto de la revista: GENETICA MEDICA Año: 2020 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Pruebas Genéticas / Regulador de Conductancia de Transmembrana de Fibrosis Quística / Genética Médica Tipo de estudio: Prognostic_studies Límite: Humans País/Región como asunto: America do norte Idioma: En Revista: Genet Med Asunto de la revista: GENETICA MEDICA Año: 2020 Tipo del documento: Article País de afiliación: Estados Unidos